Northern,WI  2/11/2013 (BasicsMedia)  —  As the snow continues in many parts of the US we head to Monday monring trading and here are some must knows.  The first is US Airways (NYSE:LCC) and AMR (AAMRQ.PK) have reportedly resolved key differences over valuation and management structure in their merger talks and may announce a deal late this week. The transaction could value the combined company at $10.5-11B and bring $1B in revenue and cost benefits. US CEO Doug Parker will lead the new firm and AMR’s Tom Horton will be non-executive chairman until the spring of 2014.

BlackRock (NYSE:BLK) has cut its stake in Herbalife (NYSE:HLF) by over 20% to 4.08%. The latter’s stock appeared to be untraded at the time of writing.  Novo Nordisk (NYSE:NVO) shares cratered 12.8% premarket after the FDA unexpectedly rejected the company’s Tresiba long-acting insulin and a related product called Ryzodeg. The FDA wants more cardiovascular data, which Novo doesn’t expect to be able to provide this year. Tresiba and Ryzodeg are approved in Europe and Japan, and were forecast to generate billions of dollars of sales.

Volkswagen (VLKAF.PK) is leaving its rivals in the dust in what’s seen as the Holy Grail of the auto industry: the “global car.” VW is investing $70B in its MQB “mega-platform” whereby it is taking a fundamental concept and implementing it across vehicles ranging from Skoda to Audi, Porsche and Lamborghini. One drawback, though, is that because VW vehicles share multiple parts, one recall could affect millions of cars.

AB InBev’s (NYSE:BUD) $20.1B attempt to buy the 50% of Grupo Modelo it doesn’t own could be hit by one unforeseen factor – the appointment of the slowest judge in Washington to oversee the Justice Department’s lawsuit against the deal. Last year, Judge Richard Roberts had 73 motions pending for over six months and more than 50 cases pending for over three years.

Disclaimer:  We have no position in any stock mentioned here.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.